Tyra Biosciences, Inc. Operating Income
Tyra Biosciences, Inc. (TYRA) reported Operating Income of -$49.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- Tyra Biosciences, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$49.00M.
- Tyra Biosciences, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$42.00M.
- Tyra Biosciences, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$36.52M.
- Tyra Biosciences, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$32.94M.
- Tyra Biosciences, Inc. operating income (loss) for fiscal 2025 was -$132.76M.
- Tyra Biosciences, Inc. operating income (loss) for fiscal 2024 was -$104.18M.
- Tyra Biosciences, Inc. operating income (loss) for fiscal 2023 was -$79.94M.
- Tyra Biosciences, Inc. operating income (loss) for fiscal 2022 was -$58.93M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.00M 10-Q · filed 2026-08-04 | -$91.00M 10-Q · filed 2026-08-04 | -$127.52M derived: sum of 3 quarters · filed 2026-08-04 | -$160.46M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$42.00M 10-Q · filed 2026-05-13 | -$78.51M derived: sum of 2 quarters · filed 2026-05-13 | -$111.46M derived: sum of 3 quarters · filed 2026-05-13 | -$142.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$36.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$69.46M derived: sum of 2 quarters · filed 2026-03-02 | -$100.91M derived: sum of 3 quarters · filed 2026-08-04 | -$132.76M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$32.94M 10-Q · filed 2025-11-05 | -$64.40M derived: sum of 2 quarters · filed 2026-08-04 | -$96.25M 10-Q · filed 2025-11-05 | -$125.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$31.45M 10-Q · filed 2026-08-04 | -$63.30M 10-Q · filed 2026-08-04 | -$93.05M derived: sum of 3 quarters · filed 2026-08-04 | -$121.65M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$31.85M 10-Q · filed 2026-05-13 | -$61.59M derived: sum of 2 quarters · filed 2026-05-13 | -$90.20M derived: sum of 3 quarters · filed 2026-05-13 | -$113.73M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$29.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$58.35M derived: sum of 2 quarters · filed 2026-03-02 | -$81.88M derived: sum of 3 quarters · filed 2026-03-02 | -$104.18M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$28.60M 10-Q · filed 2025-11-05 | -$52.14M derived: sum of 2 quarters · filed 2025-11-05 | -$74.43M 10-Q · filed 2025-11-05 | -$100.09M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$23.53M 10-Q · filed 2025-08-14 | -$45.85M 10-Q · filed 2025-08-14 | -$71.49M derived: sum of 3 quarters · filed 2025-08-14 | -$95.45M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$22.32M 10-Q · filed 2025-05-08 | -$47.96M derived: sum of 2 quarters · filed 2025-05-08 | -$71.92M derived: sum of 3 quarters · filed 2025-05-08 | -$87.93M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$25.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$49.60M derived: sum of 2 quarters · filed 2025-03-27 | -$65.61M derived: sum of 3 quarters · filed 2025-03-27 | -$79.94M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$23.96M 10-Q · filed 2024-11-07 | -$39.98M derived: sum of 2 quarters · filed 2024-11-07 | -$54.31M 10-Q · filed 2024-11-07 | -$69.33M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$16.01M 10-Q · filed 2024-08-07 | -$30.35M 10-Q · filed 2024-08-07 | -$45.37M derived: sum of 3 quarters · filed 2024-08-07 | -$59.01M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$14.33M 10-Q · filed 2024-05-09 | -$29.35M derived: sum of 2 quarters · filed 2024-05-09 | -$43.00M derived: sum of 3 quarters · filed 2024-05-09 | -$58.42M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$28.66M derived: sum of 2 quarters · filed 2024-03-19 | -$44.09M derived: sum of 3 quarters · filed 2024-03-19 | -$58.93M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$13.64M 10-Q · filed 2023-11-07 | -$29.07M derived: sum of 2 quarters · filed 2023-11-07 | -$43.91M 10-Q · filed 2023-11-07 | -$53.84M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$15.43M 10-Q · filed 2023-08-10 | -$30.26M 10-Q · filed 2023-08-10 | -$40.19M derived: sum of 3 quarters · filed 2023-08-10 | -$46.83M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$14.83M 10-Q · filed 2023-05-04 | -$24.77M derived: sum of 2 quarters · filed 2023-05-04 | -$31.40M derived: sum of 3 quarters · filed 2023-05-04 | -$36.91M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$9.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$16.57M derived: sum of 2 quarters · filed 2023-03-22 | -$22.08M derived: sum of 3 quarters · filed 2023-03-22 | -$26.29M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$6.64M 10-Q · filed 2022-11-03 | -$12.15M derived: sum of 2 quarters · filed 2022-11-03 | -$16.36M 10-Q · filed 2022-11-03 | -$20.03M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$5.51M 10-Q · filed 2022-08-04 | -$9.72M 10-Q · filed 2022-08-04 | -$13.40M derived: sum of 3 quarters · filed 2022-08-04 | -$15.73M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$4.21M 10-Q · filed 2022-05-05 | -$7.89M derived: sum of 2 quarters · filed 2022-05-05 | -$10.22M derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | -$3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$6.01M derived: sum of 2 quarters · filed 2022-03-03 | -$9.30M 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$2.33M 10-Q · filed 2021-11-03 | -$5.62M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |